Sanofi SA backed out of its $750 million effort to advance Maze Therapeutics Inc.’s oral Pompe disease candidate, MZE-001, after the U.S. FTC filed a federal lawsuit to block the deal, claiming the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback